Loading

Please wait...

Anoro ellipta

Generic Name: umeclidinium and vilanterol (ue ME kli DIN ee um and vye LAN ter ol)
Brand Names: Anoro Ellipta
Anoro (umeclidinium and vilanterol inhalation powder) is used to treat chronic obstructive pulmonary disease (COPD). Includes Anoro side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Anoro ellipta

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Anoro Ellipta is an inhalation powder containing a combination of umeclidinium and vilanterol. Umeclidinium and vilanterol both work by relaxing muscles in the airways to improve breathing. Anoro Ellipta is used to prevent airflow obstruction and reduce flare-ups in adults with COPD (chronic obstructive pulmonary disease), including bronchitis and emphysema. Anoro Ellipta is for use only in people with COPD and should not be used to treat asthma. Anoro Ellipta is for use only in people with chronic obstructive pulmonary disease (COPD) and should not be used to treat asthma. Learn more

Anoro ellipta Medicare Coverage

Overview

Does Medicare cover Anoro ellipta?

Yes

91% of Medicare Part D and Medicare Advantage plans cover this drug.
How much is my Anoro ellipta co-pay with Medicare?

It depends. Which coverage stage are you in? Click on a tab below…

CO-PAY RANGE

$42 – $464

In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.

Ways to Save on Anoro ellipta

Here are some ways that may lower the cost of your anoro ellipta prescription.

  • Instead of Medicare, Use a USA Rx Coupon

    If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.

Anoro ellipta Side Effects

Anoro Ellipta Side Effects

Note: This document contains side effect information about umeclidinium / vilanterol. Some of the dosage forms listed on this page may not apply to the brand name Anoro Ellipta.

For the Consumer

Applies to umeclidinium / vilanterol: inhalation powder

Warning

Inhalation route (Powder)

Asthma-related death: Long-acting beta(2)-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) with placebo added to the usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including vilanterol, one of the active ingredients in the umeclidinium/vilanterol combination. The safety and efficacy of umeclidinium / vilanterol in patients with asthma have not been established. Umeclidinium / vilanterol is not indicated for the treatment of asthma.

Along with its needed effects, umeclidinium / vilanterol may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking umeclidinium / vilanterol:

Less common

  • Body aches or pain
  • chest pain
  • congestion
  • cough
  • dryness or soreness of the throat
  • fever
  • headache
  • hoarseness
  • pain or tenderness around the eyes and cheekbones
  • stuffy or runny nose
  • tender, swollen glands in the neck
  • tightness of the chest
  • trouble breathing
  • trouble swallowing
  • voice changes

Rare

  • Chest discomfort
  • dizziness
  • fainting
  • fast or irregular heartbeat
  • nausea
  • pain or discomfort in the arms, jaw, back, or neck
  • sweating
  • vomiting

Some side effects of umeclidinium / vilanterol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Diarrhea
  • difficulty having a bowel movement (stool)
  • muscle spasms

Rare

  • Acid or sour stomach
  • belching
  • burning, dry, or itching eyes
  • discharge or excessive tearing
  • dry mouth
  • heartburn
  • indigestion
  • lack or loss of strength
  • rash or itching skin
  • redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
  • stomach discomfort, upset, or pain

For Healthcare Professionals

Applies to umeclidinium / vilanterol: inhalation powder

General

The most common adverse reaction was nasopharyngitis (9%).

Endocrine

Common (1% to 10%): Diabetes Mellitus

Gastrointestinal

Common (1% to 10%): Constipation, dry mouth, diarrhea, nausea, abdominal pain, toothache

Uncommon (0.1% to 1%): Dyspepsia, gastroesophageal reflux disease, vomiting

Genitourinary

Common (1% to 10%): Urinary tract infection

Frequency not reported: Signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination)

Musculoskeletal

Common (1% to 10%): Pain in extremity, muscle spasms, neck pain, back pain, arthralgia

Uncommon (0.1% to 1%): Musculoskeletal chest pain

Nervous system

Common (1% to 10%): Headache

Postmarketing reports: Dysgeusia, tremor

Other

Common (1% to 10%): Vertigo

Uncommon (0.1% to 1%): Asthenia

Respiratory

Common (1% to 10%): Pharyngitis, sinusitis, nasopharyngitis, lower respiratory tract infection, upper respiratory tract infections, cough, chest pain, pleuritic pain, viral respiratory tract infection, oropharyngeal pain

Uncommon (0.1% to 1%): Productive cough, chest discomfort

Frequency not reported: Paradoxical bronchospasm

Cardiovascular

Uncommon (0.1% to 1%): Atrial fibrillation, ventricular extrasystoles, supraventricular extrasystoles, myocardial infarction, rhythm idioventricular, tachycardia, supraventricular tachycardia

Frequency not reported: Symptoms of increases in pulse rate, systolic or diastolic blood pressure

Postmarketing reports: Palpitations

Dermatologic

Uncommon (0.1% to 1%): Pruritus, rash

Ocular

Uncommon (0.1% to 1%): Conjunctivitis

Frequency not reported: Worsening of narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema)

Hypersensitivity

Postmarketing reports: Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria

Psychiatric

Postmarketing reports: Anxiety

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Anoro Ellipta (www.drugs.com/anoro-ellipta.html).